Ramarathinam Nagarajan, MD
Allergy & Immunology · Minneapolis, MNNPI 1689636482
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations.
Across 92 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$128
- Pharming Healthcare, Inc.$116
- AstraZeneca$106
- Octapharma USA, Inc.$99
- CSL Behring$97
- Pfizer$90
- plus $881 from 20 others
What the payments were for
- Food & beverage$1,49198%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $128 |
| Pharming Healthcare, Inc. | 7 | $116 |
| AstraZeneca | 7 | $106 |
| Octapharma USA, Inc. | 5 | $99 |
| CSL Behring | 6 | $97 |
| Pfizer | 4 | $90 |
| Sanofi | 7 | $89 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| GSK | 5 | $81 |
| Biocryst US Sales Co., LLC | 5 | $73 |
| Optinose US, Inc. | 4 | $70 |
| Amgen | 4 | $65 |
| Ionis Pharmaceuticals, Inc. | 3 | $53 |
| Phadia US Inc. | 3 | $52 |
| Aimmune Therapeutics, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $44 |
| Philips North America LLC | 3 | $39 |
| Cycle Pharmaceuticals Inc | 2 | $34 |
| Genentech USA, Inc. | 2 | $32 |
| Seqirus USA Inc | 1 | $30 |
| Boehringer Ingelheim | 1 | $20 |
| Biocryst Pharmaceuticals, Inc. | 1 | $16 |
| Bio Products Laboratory USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$1,516 in reported general payments places this provider in the 70th percentile of 57 allergy & immunology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CinryzeC1 Esterase Inhibitor | 12 | $2,850,425 |
| FirazyrIcatibant Acetate | 12 | $789,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 151 | $155,378 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $28,603 |
| Zafirlukast | 128 | $15,894 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,856 |
| Fluticasone Propionate HfaFluticasone Propionate | 13 | $3,096 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,055 |
| Epinephrine | 16 | $3,055 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,917 |
| Mometasone Furoate | 30 | $2,555 |
| Fluticasone Propionate | 125 | $2,017 |
| Azelastine Hcl | 50 | $1,387 |
| Ventolin HfaAlbuterol Sulfate | 17 | $1,064 |
| Famotidine | 30 | $478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cinryze, Firazyr | $44 | $3,640,19924 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $81 | $183,981189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 57 allergy & immunology providers in Minnesota.
Other allergy & immunology in Minneapolis
- Nancy OttMinneapolis$23K
- Hannelore BruckerMinneapolis$201
- Joshua DornMinneapolis$125
- Supriya VaradarajuluMinneapolis$85
- John SweetMinneapolis$46
- Nicole ChaseSaint Paul$1.8M
- Jason RaaschPlymouth$153K
- Thanai PongdeeRochester$58K
- Elina JerschowRochester$45K
- David LoweRochester$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.